Edgewise Therapeutics (EWTX) grants 50,000 RSUs and 100,000 options to CBO
Rhea-AI Filing Summary
Edgewise Therapeutics, Inc. reported that Chief Business Officer Derakhshan Behrad had RSUs for 5,781 and 7,500 shares convert into common stock on August 12, 2026. A total of 5,100 shares were sold in multiple trades to cover statutory tax withholding obligations under a sell-to-cover arrangement, which the company states was not a discretionary sale. Behrad also received equity awards of 50,000 RSUs, vesting in four annual installments beginning August 12, 2027, and a stock option for 100,000 shares vesting monthly over 48 months beginning September 12, 2026.
Positive
- None.
Negative
- None.
Insider Trade Summary
Exercise and sale activity reported; no spread calculated
Exercise and Sale
10 txns
Insider
Derakhshan Behrad
Role
Chief Business Officer
Sold
5,100 shs ($223K)
Approx. gross sale proceeds
$223K
Approx. exercise cost
$0.00
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Stock Units F6 | 5,781 | $0.00 | $0.00 |
| Exercise | Restricted Stock Units F7 | 7,500 | $0.00 | $0.00 |
| Grant/Award | Restricted Stock Units F8 | 50,000 | $0.00 | $0.00 |
| Grant/Award | Stock Option (Right to Buy) F9 | 100,000 | $0.00 | $0.00 |
| Exercise | Common Stock | 5,781 | $0.00 | $0.00 |
| Exercise | Common Stock | 7,500 | $0.00 | $0.00 |
| Sale | Common Stock F1, F2 | 2,171 | $43.7934 | $95K |
| Sale | Common Stock F1, F3 | 304 | $44.5018 | $14K |
| Sale | Common Stock F1, F4 | 150 | $44.4433 | $7K |
| Sale | Common Stock F1, F5 | 2,475 | $43.6984 | $108K |
Holdings After Transaction:
Restricted Stock Units — 84,063 shares (Direct);
Stock Option (Right to Buy) — 100,000 shares (Direct);
Common Stock — 31,826 shares (Direct)
Footnotes (9)
- F1. Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary sale by the Reporting Person.
- F2. The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $43.30 to $44.145, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F3. The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $44.47 to $44.54, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F4. The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $44.415 to $44.50, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F5. The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $43.29 to $44.14, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F6. Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2025.
- F7. Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2026.
- F8. Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2027.
- F9. 1/48th of the shares subject to the option vest each month beginning on September 12, 2026, subject to the Reporting Person continuing as a service provider through each vest date.
Key Figures
RSUs converted to common stock: 5,781 shares
Additional RSUs converted: 7,500 shares
Shares sold to cover taxes: 5,100 shares
+3 more
6 metrics
RSUs converted to common stock
5,781 shares
RSUs converting into Edgewise Therapeutics common stock on August 12, 2026
Additional RSUs converted
7,500 shares
RSUs converting into Edgewise Therapeutics common stock on August 12, 2026
Shares sold to cover taxes
5,100 shares
Common stock sold on August 12, 2026 to satisfy statutory tax withholding obligations
New RSU grant
50,000 RSUs
RSUs vesting in four annual installments beginning August 12, 2027
New stock option grant
100,000 shares
Option vests 1/48th monthly beginning September 12, 2026
Largest sale price
$44.5018 per share
One tranche of common stock sold on August 12, 2026
Key Terms
sell-to-cover, Restricted Stock Units ("RSUs"), statutory tax withholding obligations, contingent right, +1 more
5 terms
sell-to-cover financial
"sale satisfies the minimum statutory tax withholding obligations to be funded by a "sell-to-cover""
Sell-to-cover is when part of newly issued or exercised company stock is immediately sold to pay required taxes and fees, so the recipient keeps the remaining shares. For investors this matters because it reduces the number of shares insiders or employees actually hold after a grant, can create small, routine share sales that aren’t signal of cashing out, and slightly increases share supply on the market—like selling a portion of a paycheck to cover the tax bill.
Restricted Stock Units ("RSUs") financial
"Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration"
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
statutory tax withholding obligations financial
"shares sold to cover the statutory tax withholding obligations in connection with the vesting of RSUs"
contingent right financial
"each of which represent a contingent right to receive one share of common stock"
service provider financial
"subject to the Reporting Person continuing as a service provider through each vest date"
FAQ
What equity awards did Edgewise Therapeutics (EWTX) grant to Derakhshan Behrad?
Edgewise Therapeutics granted Derakhshan Behrad 50,000 Restricted Stock Units and a stock option for 100,000 shares of common stock. The RSUs vest in four annual installments from August 12, 2027, and the option vests monthly over 48 months from September 12, 2026.
What RSUs vested for Derakhshan Behrad at Edgewise Therapeutics (EWTX)?
On August 12, 2026, RSUs covering 5,781 shares and 7,500 shares of Edgewise Therapeutics common stock vested and were converted into shares. These RSUs were previously granted at no additional cash consideration and vest in four equal annual installments beginning in 2025 and 2026, respectively.
What are the vesting terms of Derakhshan Behrad’s new RSUs at Edgewise Therapeutics (EWTX)?
The newly granted 50,000 RSUs to Derakhshan Behrad vest in four equal annual installments starting on August 12, 2027. Each vested RSU represents a contingent right to receive one share of Edgewise Therapeutics common stock upon vesting, subject to continued service.
How does Derakhshan Behrad’s new stock option at Edgewise Therapeutics (EWTX) vest?
Behrad’s new stock option for 100,000 shares of Edgewise Therapeutics common stock vests 1/48th each month, beginning on September 12, 2026. Vesting is conditioned on Behrad continuing as a service provider through each monthly vesting date.
Were Derakhshan Behrad’s Edgewise Therapeutics (EWTX) stock sales part of a planned trading program?
The filing’s Rule 10b5-1 checkbox is not marked as a plan transaction. Instead, a footnote explains the 5,100-share sale was specifically to satisfy minimum statutory tax withholding obligations via a sell-to-cover transaction tied to RSU vesting.
AI-generated analysis. How Rhea-AI works. Not financial advice.
